Cortechs.ai | Cortechs.ai announces new capabilities for quantifying FLAIR lesions

Cortechs.ai announces new capabilities for quantifying FLAIR lesions

LesionQuant™, a NeuroQuant® product, enhances our current MRI volumetric image solution to include automated, fast and accurate FLAIR lesion segmentation and quantification.

(SAN DIEGO) Aug. 3, 2016 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce the release of LesionQuant LogoLesionQuant™ for FLAIR lesion identification, segmentation, and quantification. The addition of LesionQuant to the NeuroQuant® family of products marks a notable enhancement to NeuroQuant’s proven volumetric analysis capability by combining information from 2D or 3D FLAIR and 3D T1 MR images and providing lesion and brain structure quantification in a completely automated and optimized easy-to-read report.

Powered by Cortechs.ai’ NeuroQuant and Dynamic Atlas™ technology, LesionQuant delivers a comprehensive and trusted solution for consistent, quality-driven automated MR image analysis. LesionQuant is ready for clinical, research and clinical trial use, provides significant time savings over manual or semi-automatic lesion segmentation and quantification, and is available for a broad age range from 3 to 100 years. LesionQuant delivers further insight to clinicians by providing automated FLAIR lesion segmentation, quantification, and visualization.

“Cortechs.ai’ sole purpose is to enable superior clinical insight by advancing quantitative imaging to improve patient care,” said Guri Stark, Cortechs.ai’ CEO.  “The release of the LesionQuant product extension further solidifies NeuroQuant as the foremost solution in the evaluation of brain disorders. LesionQuant provides clinicians with objective, reliable and consistent quantitative information, aiding in their assessment of gray and white matter lesions, which can be found in a variety of neurological conditions, from Multiple Sclerosis to traumatic brain injury, as well as other neurological diseases.”

LesionQuant features and benefits:

  • Total number and volume of lesions
  • Lesion burden calculation
  • New and enlarging lesion identification and quantification
  • Color-coded lesion visualization
  • Color-coded lesion change visualization
  • Anatomical lesion distribution
  • Quantification of up to 8 relevant brain structures compared to our unique age- and gender-matched normative percentiles

LesionQuant licensing options are now available. For more information on LesionQuant, visit cortechs.ai/lesionquant.

About Cortechs.ai

Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development. Please visit cortechs.ai for further information.

More Resources

10/15/2025

Sharper Screening, Smarter Biopsies: OnQ Prostate and the Next Step in Imaging

Read to learn how OnQ Prostate goes beyond existing solutions like DynaCAD and redefines biopsy precision

10/14/2025

Cortechs.ai Acquires ZepMed to Expand AI-Powered Neuroimaging Capabilities

This strategic acquisition strengthens Cortechs.ai’s position at the forefront of radiological innovation and expands its suite of best-in-class solutions

10/07/2025

Cortechs.ai Expands Partnership with Strategic Radiology to Advance Imaging Innovation Across Private Practices

Cortechs.ai and Strategic Radiology have now broadened their alliance to include Cortechs.ai’s full suite of imaging solutions.

10/06/2025

Clinical Performance of NeuroQuant: Transforming Brain MRI Analysis

NeuroQuant has consistently demonstrated strong clinical performance across multiple conditions, including Alzheimer’s , epilepsy, TBI, and MS.

10/02/2025

WEBINAR: Navigating Category III CPT Codes for Quantitative Imaging

Leveraging Compatible CPT Codes for NeuroQuant and OnQ Prostate

09/29/2025

The Role of NeuroQuant in Supporting Alzheimer’s Disease Care

NeuroQuant equips clinicians and researchers with data that can support earlier recognition of disease, track progression, and evaluate treatment efficacy.
Scroll to Top